{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:21:59Z","timestamp":1791069719101,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T00:00:00Z","timestamp":1418342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40262-014-0223-5","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T14:06:49Z","timestamp":1418306809000},"page":"527-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacokinetics of Clobazam and N-Desmethylclobazam in Children with Dravet Syndrome Receiving Concomitant Stiripentol and Valproic Acid"],"prefix":"10.1007","volume":"54","author":[{"given":"Vincent","family":"Jullien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Chhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dulac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"issue":"9509","key":"223_CR1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(06)68182-8","volume":"367","author":"R Guerrini","year":"2006","unstructured":"Guerrini R. Epilepsy in children. Lancet. 2006;367(9509):499\u2013524.","journal-title":"Lancet"},{"issue":"6","key":"223_CR2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007691-200212000-00009","volume":"24","author":"M Contin","year":"2002","unstructured":"Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit. 2002;24(6):737\u201341.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"223_CR3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32(11):1279\u201386.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"223_CR4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/FTD.0b013e318283b49a","volume":"35","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Nishimura S, Kasai R, et al. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. Ther Drug Monit. 2013;35(3):305\u201312.","journal-title":"Ther Drug Monit"},{"issue":"9242","key":"223_CR5","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, Rey E, d\u2019Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638\u201342.","journal-title":"Lancet"},{"issue":"12","key":"223_CR6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2013\u2013drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367.","journal-title":"N Engl J Med"},{"issue":"4","key":"223_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00003088-200847040-00002","volume":"47","author":"M Tod","year":"2008","unstructured":"Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231\u201343.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"223_CR8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, Rousseau M, d\u2019Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490\u2013504.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"223_CR9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608\u201311.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"223_CR10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1128\/AAC.50.3.910-916.2006","volume":"50","author":"D Hirt","year":"2006","unstructured":"Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother. 2006;50(3):910\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"223_CR11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1552-4604.1980.tb01717.x","volume":"20","author":"JJ Vallner","year":"1980","unstructured":"Vallner JJ, Kotzan JA, Stewart JT, Honigberg IL, Needham TE, Brown WJ. Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects. J Clin Pharmacol. 1980;20(7):444\u201351.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"223_CR12","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1979.tb04665.x","volume":"7","author":"W Rupp","year":"1979","unstructured":"Rupp W, Badian M, Christ O, Hajdu P, Kulkarni RD, Taeuber K, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7(Suppl 1):51S\u20137S.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"223_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","volume":"33","author":"BJ Anderson","year":"1997","unstructured":"Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33(5):313\u201327.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"223_CR14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","volume":"35","author":"J Leon de","year":"2013","unstructured":"de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35(1):30\u201347.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"223_CR15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2013\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239\u201376.","journal-title":"Epilepsia"},{"issue":"5","key":"223_CR16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00008571-199910000-00001","volume":"9","author":"HG Xie","year":"1999","unstructured":"Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4\u2019-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9(5):539\u201349.","journal-title":"Pharmacogenetics"},{"issue":"4","key":"223_CR17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","volume":"53","author":"I Mahmood","year":"2014","unstructured":"Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53(4):327\u201346.","journal-title":"Clin Pharmacokinet"},{"key":"223_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"223_CR19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/FTD.0000000000000015","volume":"36","author":"J Saruwatari","year":"2014","unstructured":"Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T, Tanikawa K, et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in Japanese patients with epilepsy. Ther Drug Monit. 2014;36(3):302\u20139.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"223_CR20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"223_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10928-010-9173-1","volume":"38","author":"M Bouillon-Pichault","year":"2010","unstructured":"Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. J Pharmacokinet Pharmacodyn. 2010;38(1):25\u201340.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"223_CR22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2125.1987.tb03247.x","volume":"24","author":"T Pullar","year":"1987","unstructured":"Pullar T, Haigh JR, Peaker S, Feely MP. Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. Br J Clin Pharmacol. 1987;24(6):793\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"223_CR23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","volume":"108","author":"Y Inoue","year":"2014","unstructured":"Inoue Y, Ohtsuka Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725\u201331.","journal-title":"Epilepsy Res"},{"issue":"2","key":"223_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007691-199704000-00003","volume":"19","author":"MF Delgado Iribarnegaray","year":"1997","unstructured":"Delgado Iribarnegaray MF, Santo Bueldga D, Garcia Sanchez MJ, Otero MJ, Falcao AC, Dominguez-Gil A. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit. 1997;19(2):132\u20139.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"223_CR25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.2042-7158.1992.tb05514.x","volume":"44","author":"E Yukawa","year":"1992","unstructured":"Yukawa E, Higuchi S, Aoyama T. Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol. 1992;44(9):755\u201360.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"223_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00007691-199602000-00004","volume":"18","author":"CR Banfield","year":"1996","unstructured":"Banfield CR, Zhu GR, Jen JF, Jensen PK, Schumaker RC, Perhach JL, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit. 1996;18(1):19\u201329.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"223_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/clpt.1993.5","volume":"53","author":"JC Cloyd","year":"1993","unstructured":"Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther. 1993;53(1):22\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"223_CR28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0773.1990.tb00799.x","volume":"67","author":"H Bun","year":"1990","unstructured":"Bun H, Monjanel-Mouterde S, Noel F, Durand A, Cano JP. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol. 1990;67(2):136\u201340.","journal-title":"Pharmacol Toxicol"},{"key":"223_CR29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1750-1172-8-176","volume":"8","author":"R Nabbout","year":"2013","unstructured":"Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, Dubouch C, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0223-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0223-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T06:37:24Z","timestamp":1650782244000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0223-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["223"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0223-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,12]]}}}